sk biopharmaceuticals
SK Biopharmaceuticals Epilepsy Drug Wins Korean Government Funding Support
SK Biopharmaceuticals’ lead epilepsy drug, YKP3089, has been awarded funding from the Korean Drug Development Fund.
SK Biopharmaceuticals Initiates PhII Trial For Diabetic Peripheral Neuropathy Drug
South Korean pharmaceutical company SK Biopharmaceuticals has initiated a Phase II trial in the United States for its new diabetic peripheral neuropathy drug, SKL11197.